| pubmed-article:12954805 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12954805 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
| pubmed-article:12954805 | lifeskim:mentions | umls-concept:C0234421 | lld:lifeskim |
| pubmed-article:12954805 | lifeskim:mentions | umls-concept:C1181031 | lld:lifeskim |
| pubmed-article:12954805 | lifeskim:mentions | umls-concept:C0042401 | lld:lifeskim |
| pubmed-article:12954805 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:12954805 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:12954805 | lifeskim:mentions | umls-concept:C0001443 | lld:lifeskim |
| pubmed-article:12954805 | lifeskim:mentions | umls-concept:C1979963 | lld:lifeskim |
| pubmed-article:12954805 | lifeskim:mentions | umls-concept:C2003903 | lld:lifeskim |
| pubmed-article:12954805 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:12954805 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:12954805 | lifeskim:mentions | umls-concept:C0971703 | lld:lifeskim |
| pubmed-article:12954805 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12954805 | pubmed:dateCreated | 2003-9-22 | lld:pubmed |
| pubmed-article:12954805 | pubmed:abstractText | The purpose of this study was to determine the magnitude of vasodilation by CVT-3146 in different vascular beds and to compare it with that by adenosine in conscious dogs. Intravenous bolus injections of CVT-3146 (0.1-2.5 microg/kg) or adenosine (10-250 microg/kg) caused a dose-dependent increase in the coronary blood flow (CBF) and a dose-dependent decrease in the late diastolic coronary resistance. Although the maximal increase in CBF response to the two drugs was not significantly different, the ED50 of CVT-3146 and adenosine were 0.45 +/- 0.07 microg/kg and 47 +/- 7.77 microg/kg, respectively. The highest dose of CVT-3146 caused a much longer coronary vasodilation than the highest dose of adenosine. There were no significant differences in increases in cardiac output induced by higher doses of CVT-3146 or adenosine. Most importantly, CVT-3146 resulted in a smaller decrease in total peripheral resistance (TPR) compared to that seen with adenosine. In addition, CVT-3146 yielded a smaller increase in the lower body flow (LBF) than adenosine. Adenosine also caused dose-dependent renal vasoconstriction, whereas CVT-3146 did not affect the renal blood flow. The administration of CVT-3146 or adenosine caused a dose-dependent vasodilation in the mesentery, which was not significantly different from each other. In summary, CVT-3146 is a 100-fold more potent coronary vasodilator than adenosine. CVT-3146 causes smaller decreases in TPR and smaller increases in LBF than those induced by adenosine, indicating that it is more selective for coronary than peripheral vasodilation. Furthermore, CVT-3146 did not cause renal vasoconstriction. These features make CVT-3146 a better candidate for pharmacologic stress testing. | lld:pubmed |
| pubmed-article:12954805 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12954805 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12954805 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12954805 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12954805 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12954805 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12954805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12954805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12954805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12954805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12954805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12954805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12954805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12954805 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12954805 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12954805 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:12954805 | pubmed:issn | 0022-3565 | lld:pubmed |
| pubmed-article:12954805 | pubmed:author | pubmed-author:XuXiaobinX | lld:pubmed |
| pubmed-article:12954805 | pubmed:author | pubmed-author:HintzeThomas... | lld:pubmed |
| pubmed-article:12954805 | pubmed:author | pubmed-author:BelardinelliL... | lld:pubmed |
| pubmed-article:12954805 | pubmed:author | pubmed-author:LinkeAxelA | lld:pubmed |
| pubmed-article:12954805 | pubmed:author | pubmed-author:ZhaoGongG | lld:pubmed |
| pubmed-article:12954805 | pubmed:author | pubmed-author:OchoaManuelM | lld:pubmed |
| pubmed-article:12954805 | pubmed:author | pubmed-author:BelloniFranci... | lld:pubmed |
| pubmed-article:12954805 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12954805 | pubmed:volume | 307 | lld:pubmed |
| pubmed-article:12954805 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12954805 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12954805 | pubmed:pagination | 182-9 | lld:pubmed |
| pubmed-article:12954805 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:meshHeading | pubmed-meshheading:12954805... | lld:pubmed |
| pubmed-article:12954805 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12954805 | pubmed:articleTitle | Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs. | lld:pubmed |
| pubmed-article:12954805 | pubmed:affiliation | CV Therapeutics, Inc., Palo Alto, CA 94304, USA. gong.zhao@cvt.com | lld:pubmed |
| pubmed-article:12954805 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12954805 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:12954805 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:12954805 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12954805 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12954805 | lld:pubmed |
